Head and Neck Cancer News and Research

RSS

Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).

Soligenix announces personalized medicine collaboration with SciClone

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone Pharmaceuticals in the Company's oral mucositis clinical program with SGX942.

8 Jul 2013

Researchers identify biochemical pathway essential for promoting head and neck cancer

A study led by researchers at The Ohio State University Comprehensive Cancer Center-- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has identified a biochemical pathway in cancer stem cells that is essential for promoting head and neck cancer.

19 Jun 2013

Soligenix receives FDA Fast Track designation for SGX942 to treat patients with oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company, announced today that its SGX942 development program for the treatment of oral mucositis as a result of radiation and/or chemotherapy treatment in head and neck cancer patients has received "Fast Track" designation from the US Food and Drug Administration.

3 Jun 2013

Mount Sinai researchers present landmark studies at ASCO meeting

Icahn School of Medicine at Mount Sinai researchers will present several landmark studies at the 2013 American Society of Clinical Oncology meeting May 31-June 4, 2013 in Chicago, including data on the likelihood of spousal human papillomavirus oral infection, new gene signatures in melanoma, and issues with high readmission rates after cancer surgery.

3 Jun 2013

Researchers discover potential biomarkers to identify patients with head and neck cancer

Researchers from Fox Chase Cancer Center will present data at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1, which shows the discovery of potential biomarkers that may be used to identify patients with head and neck cancer whose tumors are unlikely to respond to treatment by the targeted therapy cetuximab-a type of monoclonal antibody.

1 Jun 2013

Measuring genetic diversity within tumor predicts outcomes of patients with head and neck cancer

A new measure of the heterogeneity - the variety of genetic mutations - of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer.

20 May 2013

SLU SNMA students receive Leadership in Institutional Diversity Award

A group of 40 students are part of Saint Louis University's Student National Medical Association chapter (SNMA), who are striving to reduce health disparities locally. This year, they received the Leadership in Institutional Diversity Award, a recognition given to a university for serving as an outstanding example of leadership and innovation in promoting and maintaining institutional diversity.

10 May 2013

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the first patient has been dosed in a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer coordinated by the Brown University Oncology Research Group (BrUOG).

22 Apr 2013

Researcher explores new way to deliver therapy to brain metastases from primary breast cancer

An Indiana University School of Medicine breast cancer surgeon is pursuing research that will utilize glass, gold, nanotechnology and Greek mythology hoping to vanquish breast cancer that has metastasized to the brain.

19 Apr 2013

Dental associations urge regular oral cancer examinations for early detection

Almost 42,000 Americans will be diagnosed with oral or throat cancer this year. The 5-year survival rate of those diagnosed is only slightly more than 64%. When cancer is detected and treated early, treatment-related health problems are reduced.

12 Apr 2013

Phase I results show Rogosertib is well tolerated in patients with advanced solid tumors

Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors.

10 Apr 2013

CYP1B1 protein prevents head and neck cancers, say researchers

Head and neck cancers typically begin in squamous cells that line moist surfaces inside the mouth, nose and throat. Squamous cell carcinoma of the head and neck (HNSCC) is the sixth most common type of cancer in the United States, and it is sometimes preceded by the appearance of changes inside the oral cavity called precancerous lesions.

10 Apr 2013

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.

10 Apr 2013

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.

9 Apr 2013

Looking good helps women cancer patients feel better, gives more confidence to cope with disease

A year ago, Colleen Williams was into the natural look. She seldom bothered to put on makeup and she let her long, wavy, brown hair flow free. Cancer treatment changed that. These days, when she feels well enough to go to work, Williams wears her "cute hat" to cover her newly-balding head and takes a little extra time in the morning to pencil in her thinning brows and apply concealer to make her skin look a little less gray.

30 Mar 2013

FDA clears Soligenix's IND application for SGX942 for treatment of oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company, announced today that the Food and Drug Administration has completed its review and cleared the Investigational New Drug application for SGX942 for the treatment of oral mucositis resulting from radiation and/or chemotherapy treatment in head and neck cancer patients.

27 Mar 2013

Head and Neck Cancer News and Research

Soligenix announces personalized medicine collaboration with SciClone

Researchers identify biochemical pathway essential for promoting head and neck cancer

Soligenix receives FDA Fast Track designation for SGX942 to treat patients with oral mucositis

Mount Sinai researchers present landmark studies at ASCO meeting

Researchers discover potential biomarkers to identify patients with head and neck cancer

Measuring genetic diversity within tumor predicts outcomes of patients with head and neck cancer

SLU SNMA students receive Leadership in Institutional Diversity Award

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

Researcher explores new way to deliver therapy to brain metastases from primary breast cancer

Dental associations urge regular oral cancer examinations for early detection

Phase I results show Rogosertib is well tolerated in patients with advanced solid tumors

CYP1B1 protein prevents head and neck cancers, say researchers

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Looking good helps women cancer patients feel better, gives more confidence to cope with disease

FDA clears Soligenix's IND application for SGX942 for treatment of oral mucositis

New analysis reveals online nutritional guidelines for cancer patients appear to be inconsistent

SLU researcher studies effect of bitter melon extract on treating cancer

Oral Cancer Foundation encourages dental practices to offer free oral cancer screenings in April

Sosei commences SO-1105 Phase III trial in oropharyngeal candidiasis

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News